ArticleRadiology2015
Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model.
Article in Radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of pancreatic cancer screening on life expectancy: A systematic review of modeling studies.International journal of cancer · 2023Pooled it
- A Scoping Review on Calibration Methods for Cancer Simulation Models.Medical decision making : an international journal of the Society for Medical Decision Making · 2025Article
- Can AI Be Useful in the Early Detection of Pancreatic Cancer in Patients with New-Onset Diabetes?Biomedicines · 2025Review
- Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.JCO oncology practice · 2024Article
- Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort.United European gastroenterology journal · 2023Article
- Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening.Current oncology (Toronto, Ont.) · 2022Review
- Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2022Article
- Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer.Journal of biomedical informatics · 2022Article
- Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis.International journal of cancer · 2021Article
- Screening for pancreatic cancer-a compelling challenge.Hepatobiliary surgery and nutrition · 2021Article
- CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.International journal of cancer · 2019Article
- Chronic pancreatitis changes in high-risk individuals for pancreatic ductal adenocarcinoma.Gastrointestinal endoscopy · 2019Article
- Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2018Article
- Universal cancer screening: revolutionary, rational, and realizable.NPJ precision oncology · 2018Review
- Self-Reported Questionnaire Detects Family History of Cancer in a Pancreatic Cancer Screening Program.Journal of genetic counseling · 2017Article
- Prevention of pancreatic cancer.Contemporary oncology (Poznan, Poland) · 2017Review
- Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening.Pancreas · 2016Article
- Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model.EBioMedicine · 2015Article
- Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.Radiology · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
purposeTo identify when, from the standpoint of relative risk, magnetic resonance (MR) imaging-based screening may be effective in patients with a known or suspected genetic predisposition to pancreatic cancer. MATERIALS AND
methodsThe authors developed a Markov model of pancreatic ductal adenocarcinoma (PDAC). The model was calibrated to National Cancer Institute Surveillance, Epidemiology, and End Results registry data and informed by the literature. A hypothetical screening strategy was evaluated in which all population individuals underwent one-time MR imaging screening at age 50 years. Screening outcomes for individuals with an average risk for PDAC ("base case") were compared with those for individuals at an increased risk to assess for differential benefits in populations with a known or suspected genetic predisposition. Effects of varying key inputs, including MR imaging performance, surgical mortality, and screening age, were evaluated with a sensitivity analysis. RESULTS In the base case, screening resulted in a small number of cancer deaths averted (39 of 100 000 men, 38 of 100 000 women) and a net decrease in life expectancy (-3 days for men, -4 days for women), which was driven by unnecessary pancreatic surgeries associated with false-positive results. Life expectancy gains were achieved if an individual's risk for PDAC exceeded 2.4 (men) or 2.7 (women) times that of the general population. When relative risk increased further, for example to 30 times that of the general population, averted cancer deaths and life expectancy gains increased substantially (1219 of 100 000 men, life expectancy gain: 65 days; 1204 of 100 000 women, life expectancy gain: 71 days). In addition, results were sensitive to MR imaging specificity and the surgical mortality rate.
conclusionAlthough PDAC screening with MR imaging for the entire population is not effective, individuals with even modestly increased risk may benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.